Activated recombinant factor VII and extracorporeal membrane oxygenation: Everything is all right, nothing is wrong?*

Pediatric Critical Care Medicine

Volumn 11, Issue 1, 2010, Pages 155-156

  Dominguez, Troy E ^a   Brown, Kate L ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Cardiac; Coagulation; Extracorporeal membrane oxygenation; Hemorrhage; Intensive care; Pediatrics; Recombinant factor VII

Indexed keywords

ANTIFIBRINOLYTIC AGENT; PROCOAGULANT; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; CARDIAC PATIENT; CARDIOPULMONARY BYPASS; DRUG COST; EDITORIAL; EXTRACORPOREAL OXYGENATION; FIBRINOLYSIS; HEMOSTASIS; HIGH RISK PATIENT; INTENSIVE CARE UNIT; MORBIDITY; MORTALITY; PEDIATRICS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE DYSFUNCTION; THROMBOSIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TUBE;

EID: 75149160091     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/PCC.0b013e3181b80dc1     Document Type: Editorial

References (25)

1. Brown KL, Ridout DA, Shaw M, et al.: Healthcare- associated infection in pediatric patients on extracorporeal life support: The role of multidisciplinary surveillance. Pediatr Crit Care Med 2006; 7:546-550
2. Chaturvedi RR, Macrae D, Brown KL, et al.: Cardiac ECMO for biventricular hearts after paediatric open heart surgery. Heart 2004; 90:545-551
3. Aledort LM: Activated prothrombin complex concentrates and recombinant factor VIIa in the bleeding patient: Are they appropriate and safe? J Thorac Cardiovasc Surg 2003; 126:2112-2113
4. Biswas AK, Lewis L, Sommerauer JF: Aprotinin in the management of life-threatening bleeding during extracorporeal life support. Perfusion 2000; 15:211-216
5. Reiter PD, Valuck RJ, Taylor RS: Evaluation of off-label recombinant activated factor VII for multiple indications in children. Clin Appl Thromb Hemost 2007; 13: 233-240
6. Agarwal HS, Bennett JE, Churchwell KB, et al.: Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery. Ann Thorac Surg 2007; 84:161-168
7. Brose S, Sirbu H, Engel M, et al.: Successful use of recombinant factor VIIa in a patient with intractable bleeding during extracorporeal membrane oxygenation. Thorac Cardiovasc Surg 2005; 53:389-390
8. Dement'eva II, Sandrikov VA, Charnaia MA, et al.: Use of "NovoSeven" (rFVIIa) hemostatic in patients operated with extracorporeal blood circulation. [Article in Russian] Anesteziol Reanimatol 2004; 5:11-13
9. Dominguez TE, Mitchell M, Friess SH, et al.: Use of recombinant factor VIIa for refractory hemorrhage during extracorporeal membrane oxygenation. Pediatr Crit Care Med 2005; 6:348-351
10. Lucey MA, Myburgh JA: Recombinant activated factor VII for exsanguinating haemorrhage post bilateral lung transplantation for extra-corporeal lung support-dependent respiratory failure. Anaesth Intensive Care 2003; 31:465-469
11. Preston TJ, Olshove VF Jr, Ayad O, et al.: Novoseven use in a non-cardiac pediatric ECMO patient with uncontrolled bleeding. J Extra Corpor Technol 2008; 40:123-126
12. Veldman A, Neuhaeuser C, Akintuerk H, et al.: RFVIIa in the treatment of persistent hemorrhage in pediatric patients on ECMO following surgery for congenital heart disease. Paediatr Anaesth 2007; 17:1176-1181
13. Verrijckt A, Proulx F, Morneau S, et al.: Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 2004; 127:1812-1813
14. Wittenstein B, Ng C, Ravn H, et al.: Recombinant factor VII for severe bleeding during extracorporeal membrane oxygenation following open heart surgery. Pediatr Crit Care Med 2005; 6:473-476
15. Hanley JA, Lippman-Hand A: If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 1983; 249: 1743-1745
16. Niebler RA, Punzalan RC, Marchan M, et al.: Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. Pediatr Crit Care Med 2010; 11:98-102
17. Cooper DS, Jacobs JP, Moore L, et al.: Cardiac extracorporeal life support: State of the art in 2007. Cardiol Young 2007; 17(Suppl 2): 104-115
18. Bui JD, Despotis GD, Trulock EP, et al.: Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002; 124:852-854
19. Chalwin RP, Tiruvoipati R, Peek GJ: Fatal thrombosis with activated factor VII in a paediatric patient on extracorporeal membrane oxygenation. Eur J Cardiothorac Surg 2008; 34:685-686
20. Velik-Salchner C, Sergi C, Fries D, et al.: Use of recombinant factor VIIa (Novoseven) in combination with other coagulation products led to a thrombotic occlusion of the truncus brachiocephalicus in a neonate supported by extracorporeal membrane oxygenation. Anesth Analg 2005; 101:924
21. von HC, Ziemer S, Kox WJ, et al.: Caveat against the use of feiba in combination with recombinant factor viia. J Thorac Cardiovasc Surg 2003; 126:1667-1668
22. Swaminathan M, Shaw AD, Greenfield RA, et al.: Fatal thrombosis after factor VII administration during extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth 2008; 22:259-260
23. Pang G, Donaldson A: Probable right atrial thrombus immediately after recombinant activated factor VII administration. Br J Anaesth 2007; 99:221-225
24. Lichtman AD, Carullo V, Minhaj M, et al.: Case 6-2007: Massive intraoperative thrombosis and death after recombinant activated factor VII administration. J Cardiothorac Vasc Anesth 2007; 21:897-902
25. Warren O, Mandal K, Hadjianastassiou V, et al.: Recombinant activated factor VII in cardiac surgery: A systematic review. Ann Thorac Surg 2007; 83:707-714